The choice of a primary endpoint is a matter of ongoing debate in the design of clinical oncology trials testing new treatment regimens. Overall survival (OS) time of patients serves as a gold-standard endpoint in phase III clinical trials testing first-line chemotherapy for cancers, because this outcome variable ultimately represents survival benefits from chemotherapy regimens and has minimal measurement errors.
CITATION STYLE
Hamada, T., Kosumi, K., Nakai, Y., & Koike, K. (2018). Surrogate study endpoints in the era of cancer immunotherapy. Annals of Translational Medicine, 6(S1), S27–S27. https://doi.org/10.21037/atm.2018.09.31
Mendeley helps you to discover research relevant for your work.